Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2021.2024940
Abstract: ABSTRACT Objectives: Venetoclax combinations are a new standard for patients with acute myeloid leukemia (AML). We aimed to evaluate the safety and efficacy of these combinations in a period of accelerated approval in Latin-America. Methods:… read more here.
Keywords: myeloid leukemia; aml; latin america; acute myeloid ... See more keywords
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207231155028
Abstract: Background: Patients with relapsed/refractory multiple myeloma (RRMM) usually have dismal prognostic outcomes. Venetoclax, a selective inhibitor of antiapoptotic protein B-cell lymphoma-2 (BCL-2), demonstrates antimyeloma activity in plasma cells with t(11;14) or high BCL-2 expression. Objectives:… read more here.
Keywords: safety; meta analysis; relapsed refractory; analysis ... See more keywords
First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139923
Abstract: Background: The outcome of elderly patients with Acute Myeloid Leukemia (AML) is poor and treatment options in these high-risk groups are limited. Recently, venetoclax combinations with hypomethylating agents or low dose cytarabine were approved to… read more here.
Keywords: consultancy honoraria; venetoclax based; abbvie inc; research funding ... See more keywords
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2023019634
Abstract: Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy (CIT) while their prognostic impact in the context of venetoclax-based treatments is still debated. In this prospective analysis on… read more here.
Keywords: cll treated; venetoclax based; complexity; complex karyotypes ... See more keywords
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.562558
Abstract: The past decade has witnessed major advances in our understanding of molecular biology, which led to breakthrough novel therapies, importantly including the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax. Notably, venetoclax-based combinations have improved outcomes, including both… read more here.
Keywords: venetoclax based; myeloid leukemia; combinations acute; acute myeloid ... See more keywords
MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.890871
Abstract: The prognosis of newly diagnosed patients with acute myeloid leukemia is still unfavorable in the majority of cases within the intermediate and mainly adverse genetic risk group but also in a considerable fraction of favorable-risk… read more here.
Keywords: residual disease; disease; aml; mrd ... See more keywords
Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1149298
Abstract: Introduction Combination of venetoclax and hypomethylating agents (HMAs) has become a standard of care in acute myeloid leukemia (AML) aged >75 years or who have comorbidities that preclude intensive induction chemotherapy. Methods We conducted a… read more here.
Keywords: myeloid leukemia; aml; acute myeloid; treatment ... See more keywords